Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* Diabetes mellitus, type 2, for at least 6 months~* Treatment regimens: diet and exercise, metformin as monotherapy or in combination with another oral antihyperglycemic medication (OAM), or another OAM as monotherapy. Must be able to tolerate metformin at a dose of at least 1500 milligrams (mg) daily for 6 weeks prior to randomization.~* Glycosylated hemoglobin (HbA1c) value of ≥7.0% to ≤9.5%, except participants on diet and exercise therapy who must have had HbA1c value of \>8.0% to ≤9.5%~* Body mass index (BMI) between 25 and 40 kilograms per meter squared (kg/m\^2), inclusive~* Stable weight for 3 months prior to screening~* Females of childbearing potential must test negative for pregnancy and agree to use a reliable birth control method~Exclusion Criteria:~* Diabetes mellitus, type 1~* Use of a glucagon-like peptide-1 (GLP-1) analog (for example, exenatide) within 6 months prior to screening or are being treated with insulin~* Gastric emptying abnormality, history of bariatric surgery, or chronic use of drugs that affect gastrointestinal motility~* Use of medications to promote weight loss~* Clinically-relevant cardiovascular event within 6 months prior to screening~* Poorly controlled hypertension~* Electrocardiogram (ECG) reading considered outside the normal limits or indicating cardiac disease~* Liver disease, hepatitis, chronic pancreatitis, idiopathic acute pancreatitis, or alanine transaminase (ALT) levels \>3.0 times the upper limit of normal~* Serum creatinine ≥1.5 milligrams per deciliter (mg/dL) or a creatinine clearance \<60 milliliters per minute (mL/minute)~* Uncontrolled diabetes, defined as \>2 episodes of ketoacidosis or hyperosmolar state requiring hospitalization in the 6 months prior to study entry.~* Uncontrolled endocrine or autoimmune abnormality~* History of a transplanted organ~* Chronic use of systemic glucocorticoid therapy~* Active or untreated malignancy~* Use of central nervous system (CNS) stimulants

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 3.0 mg LY2189265 (Type: EXPERIMENTAL): LY2189265 (Dulaglutide): 3.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks
- 2.0 mg LY2189265 (Type: EXPERIMENTAL): LY2189265 (Dulaglutide): 2.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks
- 1.5 mg LY2189265 (Type: EXPERIMENTAL): LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks
- 1.0 mg LY2189265 (Type: EXPERIMENTAL): LY2189265 (Dulaglutide): 1.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks
- 0.75 mg LY2189265 (Type: EXPERIMENTAL): LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks
- 0.5 mg LY2189265 (Type: EXPERIMENTAL): LY2189265 (Dulaglutide): 0.5 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks
- 0.25 mg LY2189265 (Type: EXPERIMENTAL): LY2189265 (Dulaglutide): 0.25 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks
- Sitagliptin (Type: ACTIVE_COMPARATOR): Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks~Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks
- Placebo/Sitagliptin (Baseline Through 104 Weeks) (Type: PLACEBO_COMPARATOR): Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks~Placebo: tablet, administered orally, once daily for 26 weeks~Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).